08/12/2025
8:07 AM | Adage Capital Management, L.P. (Filed by)
Eyepoint Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
08/06/2025
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/29/2025
8:35 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K/A | |
07/29/2025
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/11/2025
3:06 PM | Duker Jay S. (Reporting)
Eyepoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/11/2025
3:06 PM | Eyepoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/11/2025
3:07 PM | Eyepoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/08/2025
6:30 AM | Eyepoint Pharmaceuticals (Subject)
FEDERATED HERMES, INC. (Filed by)
FEDERATED HERMES, INC. (Filed by)
| Form SCHEDULE 13G/A | |
06/25/2025
4:13 PM | Duker Jay S. (Reporting)
Eyepoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2025
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/27/2025
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for EYPT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Eyepoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. |
05/15/2025
3:06 PM | Eyepoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2025
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form DEFA14A | |
05/07/2025
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/28/2025
3:10 PM | Eyepoint Pharmaceuticals (Filer)
| Form DEFA14A | |
03/20/2025
3:06 PM | Duker Jay S. (Reporting)
Eyepoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/06/2025
3:05 PM | Eyepoint Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/05/2025
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/04/2025
8:00 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/14/2025
5:37 PM | Eyepoint Pharmaceuticals (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SCHEDULE 13G/A | |
02/12/2025
8:33 AM | Adage Capital Management, L.P. (Filed by)
Eyepoint Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
02/11/2025
5:19 PM | Duker Jay S. (Reporting)
Eyepoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/11/2025
5:19 PM | Eyepoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/11/2025
5:19 PM | Elston George (Reporting)
Eyepoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2025
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/27/2025
11:58 AM | Eyepoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SCHEDULE 13G/A | |
01/13/2025
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/08/2025
3:11 PM | Eyepoint Pharmaceuticals (Issuer)
Sanders Reginald J. (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/08/2025
3:14 PM | Eyepoint Pharmaceuticals (Issuer)
Sanders Reginald J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/08/2025
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/07/2025
3:03 PM | Duker Jay S. (Reporting)
Eyepoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | Eyepoint Pharmaceuticals (Issuer)
Landis John B. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | Eyepoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | Elston George (Reporting)
Eyepoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | Eyepoint Pharmaceuticals (Issuer)
Ribeiro Ramiro (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | DICICCO WENDY F (Reporting)
Eyepoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | Duty Stuart (Reporting)
Eyepoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | ANDO GORAN (Reporting)
Eyepoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:05 PM | Eyepoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:05 PM | Eyepoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/04/2024
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
A New Way to Double Your Retirement Income? (Ad) Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities.
If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for. Click here to see how to turn your savings into a monthly income machine. |
11/14/2024
2:10 PM | Cormorant Asset Management, LP (Filed by)
Eyepoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/12/2024
1:31 PM | Eyepoint Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/12/2024
8:33 AM | Adage Capital Management, L.P. (Filed by)
Eyepoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/07/2024
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/06/2024
7:54 AM | Eyepoint Pharmaceuticals (Subject)
FEDERATED HERMES, INC. (Filed by)
FEDERATED HERMES, INC. (Filed by)
| Form SC 13G | |
11/04/2024
10:57 AM | Eyepoint Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
10/31/2024
3:16 PM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/31/2024
11:51 AM | Eyepoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SCHEDULE 13G/A | |
10/30/2024
3:20 PM | Eyepoint Pharmaceuticals (Filer)
| Form 424B5 | |
10/28/2024
4:17 PM | Eyepoint Pharmaceuticals (Filer)
| Form 424B5 | |
10/28/2024
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/24/2024
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/23/2024
3:34 PM | ADAMIS ANTHONY P (Reporting)
Eyepoint Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/22/2024
2:24 PM | BlackRock, Inc. (Filed by)
Eyepoint Pharmaceuticals (Subject)
| Form SC 13G | |
10/15/2024
10:58 AM | Eyepoint Pharmaceuticals (Subject)
GUYER DAVID R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/05/2024
3:02 PM | Eyepoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2024
3:02 PM | Eyepoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/04/2024
6:05 AM | Eyepoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
MarketBeat All Access